How the EU IVDR Impacts Both the Development & Access to the Pharmaceutical Industry’s Precision Medicines
Time: 8:30 am
day: Conference Day Two - AM
Details:
- The EU IVDR introduces new impactful requirements for pharma’ for the use of IVDs both before and after the approval of precision medicines.
- Shortages of both CE marked and in-house IVDs , for use with precision medicines, may impact access to key treatments.
- The approval process for IVDs used within clinical trials of precision medicines may create impactful delays.
